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Abstract
microRNAs (miRNAs) are a class of small non-coding RNAs, which have been shown important
to a wide range of biological process by post-transcriptionally regulating the expression of protein-
coding genes. miRNAs have been demonstrated essential to normal cardiac development and
function. Recently, numerous studies indicate miRNAs are involved in cardiac regeneration and
cardiac disease, including cardiac hypertrophy, myocardial infarction and cardiac arrhythmia.
These observations suggest miRNAs play important roles in cardiology. In this review, we
summarize the recent progress of studying miRNAs in cardiac regeneration and cardiac disease.
We also discuss the diagnostic and therapeutic potential of miRNAs in heart disease.
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Historically, we have been focusing on protein-coding genes over the past decades and
proteins have often been viewed as the final gene products that mediate most of the
biological function in a given cell. However, more and more recent studies indicated that
non-coding RNAs (ncRNAs) participate in the regulation of the expression of protein-
coding genes therefore play essential roles in many biological processes. These findings
uncovered that noncoding RNAs orchestrate a hidden layer of gene regulation network [1,2].
microRNAs (miRNAs), a class of small non-coding RNAs (~20 nucleotides) [3,4], were
first discovered in C. elegans two decades ago [5,6]. Now we know that miRNAs are
present in virtually all plants [7] and animals [8–10]. Many miRNAs are evolutionary
conserved, indicating they may serve as an ancient component of genetic regulation [11–14].
miRNAs are transcribed by RNA polymerase II (RNA-pol II) as primary transcripts
(primiRNAs) [15], which contain stem-loop hairpin structure, and then subsequently
processed by RNase III enzymes Drosha and Dicer [16–19]. The processed products are ~22
nt long miRNA duplexes with 2 nt overhangs on the 3′ end [20,21]. Dicer also contributes to
the loading of mature miRNAs into the RNA-induced silencing complex (RISC). RISC is
responsible for the gene silencing observed due to miRNA expression and RNA interference
[22,23]. After loading into the RISC complex, miRNAs guide the RISC complex to their
target genes by binding to imperfect complementary sites within the 3′ untranslated regions
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t(3′UTRs) [24]. Studies have shown that miRNA can also bind to the 5′ untranslated regions
(5′UTRs) and even the open reading frames (ORFs) of their target mRNAs [25]. miRNAs
repress the expression of their target genes by mRNA destabilization and/or translational
repression [24,26]. Moreover, miRNAs were also reported to cause histone modification
and/or DNA methylation of promoter sites, which affects the expression of target genes
[27,28].
1 miRNAs in cardiac development
Global disruption of the expression of all miRNAs in the heart is the first step to understand
the function of miRNAs in cardiac development and physiology. Dicer, an RNase III
endoribonuclease is a critical enzyme for the maturation of most miRNAs. Conventional
deletion of Dicer caused early embryonic lethality in mice [29] and zebrafish [30,31], prior
to the development of the heart. In order to study the function of miRNAs in cardiac
development, studies using cardiac- specific promoter-driven Cre line, such as Nkx2.5-Cre
and α-MHC-Cre, to knockout Dicer in cardiac linage have been performed. Disrupting
miRNA expression in early embryonic stage using Nkx2.5-Cre leads to improperly
compacted ventricular myocardium in mutant embryos [32]. While α-MHC-Cre-mediated
conditional deletion of Dicer causes postnatal lethality due to dilated cardiomyopathy and
heart failure [33]. Additionally, tamoxifen-induced cardiacspecific deletion of Dicer in adult
hearts induces spontaneously cardiac hypertrophy and fetal gene expression [34]. Moreover,
cardiac-specific knockout of Drosha leads to similar cardiac defects with that of cardiac-
specific Dicer mutant, further supporting the importance of miRNAs in cardiac development
and function [35].
Studies of miRNA expression profiling have indicated that although many miRNAs are
expressed ubiquitously throughout the mammalian organisms, some miRNAs have tissue-
specific expression patterns [36]. Focusing on striated muscles like cardiomyocytes and
skeletal muscle cells, previous studies found that miR-1/133 cluster is the most abundantly
expressed miRNA in the heart whose expression was detected as early as embryonic day
13.5 (E13.5) [37]. The expression of this miRNA cluster can be regulated by multiple
myogenic transcription factors, including MyoD [38], Mef2 [39], and SRF [40]. miR-1,
miR-133, together with miR-206 [41], miR-208a/b [42,43] and miR-499 [44] have been
identified specifically expressed in striated muscles (and therefore referred to as
“myomiRs”). Gain- and loss-of-function studies demonstrated that myomiRs play key roles
in cardiomyocyte proliferation, cardiac morphogenesis and stress responsive cardiac
remodeling [40,42,43]. Interestingly, recent reports showed that miRNAs, which are not
restricted to striated muscles, are also required for the normal cardiogenesis. miR-138 is
required for the elongation of ventricular cardiomyocytes by repressing the expression of
cspg2 and notch1b, which are normally restricted to the atrioventricular canal region, in the
ventricle in zebrafish [45]. Loss-of-function of miR-218 in zebrafish affects the endocardial
migration, and therefore affects the heart tube formation by regulating the Vegf singling
[46].
2 miRNAs mediate cardiac regeneration
Mammalian adult cardiomyocytes are terminally differentiated cells with very limited
regenerative ability. In response to injury and cell loss, adult mammalian hearts are unable
to fully regenerate. However, recent evidences indicate that human cardiomyocytes are able
to proliferate during the postnatal life [47,48]. Intriguingly, it was discovered that in rodent
models hearts before postnatal day 7 have a good regenerative ability. Young hearts can
regenerate the cardiac tissue without the formation of scar (fibrosis) after resection of the
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tventricle apex. However, the cardiac regenerative ability is lost by 7 d of age due to a
significant decrease of the proliferative rate of cardiomyocytes [49].
Both protein-coding genes and non-coding RNA genes have been suggested to participate in
the regulation of cardiac regeneration. For protein-coding genes, inhibition of p38 MAP
kinase was found to induce mitosis in adult mammalian cardiomyocytes [50]. Treatment
with FGF1 and p38 MAP kinase inhibitors regenerates the heart, reduces scarring, and
improves cardiac function in rats with cardiac injury [51]. Non-coding RNAs, especially
miRNAs, have also been found playing an important role in cardiac regeneration. miRNA
profiling analyses indicated that the expression of miRNAs is regulated during cell cycle
exit of cardiomyocyte shortly after born. Through profiling and comparing miRNA
expression between postnatal day 1 and day 10 rat cardiomyocytes, Porrello et al. [52]
identified members of the miR-15 family, including miR-195, miR-15a, miR-15b, miR-16
and miR-497, as important regulators of postnatal cardiomyocyte mitotic arrest. Further
gain- and loss-of-function studies demonstrated that cardiomyocytes proliferation can be
inhibited by this family of miRNAs through the repression of multiple cell cycle regulators,
including the checkpoint kinase 1 (Chek1). Interestingly, miR-15 family was also shown up-
regulated in cardiac ischemia and heart failure [53] and it was reported that miR-15 induces
apoptosis by targeting anti-apoptotic factor Bcl2 [54]. Together, these studies suggest that
the miR-15 family may play distinct roles in cardiomyocytes at different developmental and/
or pathological conditions.
To further investigate if miRNAs can increase cardiomyocytes proliferation, Eulalio et al.
[55] performed a high-content, fluorescence-microscopy-based, high-throughput screening
in neonatal rat cardiomyocytes using a whole-genome miRNA library. They identified about
40 miRNAs that strongly increased both DNA synthesis and cytokinesis in neonatal mouse
and rat cardiomyocytes [55]. Two of these miRNAs, miR-590 and miR-199a, were further
demonstrated to induce cardiomyocyte proliferation both in vitro and in vivo. Most recently,
our group also discovered that other miRNAs can increase cardiomyocytes proliferation.
Using both transgenic (TG) and knockout (KO) mice model, we demonstrated that
miR-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation. More
specifically, we identified miR-19a/b as the major contributors among the miR-17-92 cluster
to the regulation of the cardiomyocyte proliferation. We further identified the tumor
suppressor PTEN as a direct target of miR-17-92 repressed. These studies uncovered that
miR-17-92 plays a key role in the regulation of cardiomyocytes proliferation in embryonic,
postnatal and adult hearts [56].
Over the past several years, the approaches to differentiating embryonic stem cells and
induced pluripotent stem cells (iPSCs) into cardiomyocytes to compensate the loss of
cardiomyocytes during cardiac injury have raised the hope for patients with cardiac
infarction and heart failure [57,58]. However, the potential tumorigenicity is a big concern
for these strategies of cardiac regeneration [59,60]. Most recently, an exciting breakthrough
was achieved in which Ieda et al. [61] found a new strategy to direct reprogram fibroblast
(CF) into cardiomyocyte (CM) through the combination of three cardiac-specific
transcriptional factors, Gata4, Mef2c and Tbx5 (GMT) in vitro. Intriguingly, Qian et al. [62]
and Song et al. [63] demonstrated that the direct reprogramming was also achievable in vivo.
These investigators reported that they were able to use three factors (GMT) or four cardiac
transcription factors, GATA4, HAND2, MEF2C, and TBX5 (GHMT) respectively, to
reprogram cardiac fibroblasts or even mouse tail-tip fibroblasts into beating cardiomyocyte-
like cells in vivo. More importantly, reprogramming cardiac fibroblasts into cardiomyocytes
in vivo was shown to improve cardiac function and reduce cardiac fibrosis in a mouse model
of myocardial infraction. It is not known whether miRNAs are involved in the process of
reprogramming which is induced by cardiac transcription factors.
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tGiven their characteristics of tiny and mighty, it is not surprising that a recent report
indicated that a combination of miR-1, miR-133, miR-208, and miR-499 was able to directly
induce the cellular reprogramming of fibroblasts into cardiomyocyte-like cells in vitro [64].
The investigators demonstrated that miR-1 alone is sufficient to induce the fibroblast to
cardiomyocyte reprogramming. However, this reprogramming efficiency was dramatically
enhanced when miRNAs 133, 208 and 499 were added. Interestingly, the process of
reprogramming was further enhanced about 10-fold after JAK inhibitor I treatment.
Moreover, administration of miRNAs into ischemic mouse myocardium resulted in direct
conversion of cardiac fibroblasts to cardiomyocytes in situ. Recently, Nam et al. [65] used a
combination of transcription factors and miRNAs to induce the direct reprogramming of
fibroblasts into cardiomyocyte-like cells. They treated human fibroblasts with four
transcriptional factors, GATA-4, Hand2, Tbx5 and Myocardin [66], together with two
miRNAs, miR-1 and miR-133. Portion of the treated human fibroblasts were reprogrammed
into cells with sarcomere-like structures, showing spontaneous contractility after 4–11
weeks in culture. Besides the phenotypic changes, the investigators found that the
transcriptome of reprogrammed cells also shifted toward cardiomyocytes. These data
indicated miRNAs could function with cardiac transcriptional factors to synergistically
control cardiac reprogramming.
Unlike adult skeletal muscle, which contains a large population of satellite cells to serve as
stem cells to regenerate the lost muscle mass in response to injury, the adult heart only has a
very limited population of stem cells or progenitor cells. Studies indicated that these cells
can be differentiated into cardiomyocyte in vitro. Interestingly, miRNAs are shown to
contribute to the differentiation of cardiac stem cells (CSCs) into mature, working
cardiomyocytes. Hosoda et al. [67] identified that miR-499 promotes the differentiation of
human CSCs (hCSCs) into mechanically integrated cardiomyocytes by repressing its targets,
Sox6 and Rod1. More importantly, the miR-499-overexpressed hCSCs injected into the
infracted mouse hearts could enhance cardiac differentiation and further contribute to a
better improvement of the cardiac function of the injured hearts.
3 miRNAs regulate cardiac remodeling
Cardiac remodeling, which is defined as alteration in the structure (dimensions, mass, shape)
of the heart, is one of the major responses of the heart to biomechanical stress and
pathological stimuli. Among them, cardiac hypertrophy is anatomically defined as an
increase in the thickness of the cardiac ventricular wall, owing to enlargement of myocyte
size and/or increased fibrosis. Sustained cardiac hypertrophy often leads to end stage heart
failure. To investigate the involvement of miRNAs in this process, genome-wide profiling of
miRNA expression has been performed and dysregulated miRNAs were identified during
cardiac remodeling [68,69]. For instance, miR-21, a miRNA upregulated during
hypertrophy, was shown to promote cardiac fibroblast survival through enhancing the ERK-
MAP kinase activity [70]. Interestingly, inhibition of miR-21 via an antagomir was shown to
repress cardiac hypertrophy and fibrosis in vivo in response to stress, however, these results
could not be verified through genetic deletion of miR-21 in mice [71], indicating that
miR-21 may not be essential for the pathological remodeling of the heart. Another study
showed that isoproterenol-induced cardiac hypertrophy could be repressed when miR-23a
was knocked down. miR-23a represents another miRNA up-regulated during hypertrophy
and the repressive effect of miR-23a in cardiac hypertrophy was suggested, at least in part,
due to the repression of MuRF1, an anti-hypertrophic factor [72]. Moreover, cardiac-specific
overexpression of miR-195, another miRNA induced in hypertrophic hearts, in transgenic
mice model induces significantly cardiac hypertrophy and dilated cardiomyopathy with
unknown mechanism [53]. Recently, we and others [73,74] demonstrated that miR-22, a
miRNA enriched in cardiomyocytes but only mildly up-regulated during cardiac
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thypertrophy, significantly promotes cardiac hypertrophy in vitro. Consistently, cardiac-
specific knockout of miR-22 in mice showed the repressed cardiac hypertrophy was
accompanied with accelerated dilation [73]. Conversely, cardiac-specific overexpression of
this miRNA induced spontaneous hypertrophy growth in the heart [75]. Additional studies
showed that miR-22 represses a broad spectrum of target genes, including Sirt1, HDAC4,
PPARa and Purb, a negative regulator of SRF [73,75].
Conversely, unlike those up-regulated miRNAs, the expression of miR-93, miR-181 and
muscle-specific micro- RNAs miR-1 and miR-133a is down-regulated during cardiac
hypertrophy [53,76,77]. The miR-133a is coded by two genomic loci, miR-133a-1 and
miR-133a-2. Studies showed that inhibition of miR-133a leads to hypertrophy both in vitro
and in vivo, probably through the derepression of RhoA, Cdc42, and NELFA/WHsc2 [76].
Genetic studies indicated that deletion of both miR-133a-1 and miR-133a-2, but not each
single one alone, leads to phenotypically abnormal, even embryonic lethal in mice [78]. All
these data suggest that miR-133a is not only necessary for cardiac development, but also
required for normal cardiac functional maintenance in adult hearts. miR-208a, whose
expression was not altered in cardiac hypertrophy, has been demonstrated to be involved in
stress-dependent cardiac hypertrophy by targeting thyroid hormone receptor associated
protein 1 (THRAP1). Both gain- and loss-of-function studies demonstrated that miR-208 is
not only sufficient to induce cardiac hypertrophy but also required for the hypertrophic
growth under stress [42,43].
Cardiac fibrosis, which is defined as abnormal deposition of collagen by cardiac fibroblast,
is often observed to replace the “drop-out” of cardiomyocytes during cardiac remodeling.
Many genes have been reported to participate in the regulation of this process. It is not
surprising that miRNAs were reported to regulate cardiac fibrosis in recent years.
Connective tissue growth factor (CTGF) is a key molecule in the process of fibrosis and
therefore seemingly serves as an attractive therapeutic target [79–81]. However, it was
unknown how CTGF transcripts were regulated posttranscriptionally. Duisters et al. [82]
showed that miR-133 and miR-30 were involved in myocardial matrix remodeling through
regulating CTGF. Both miR-133 and miR-30 were found consistently down-regulated in
several models of heart failure and pathological hypertrophy. Knockdown of these miRNAs
resulted in a strong increase of CTGF levels. Conversely, overexpression of miR-133 and
miR-30c repressed the production of collagens, which was accompanied with a decrease in
CTGF expression levels. Moreover, the miR-29 family, which was predominantly expressed
in cardiac fibroblasts [83], is significantly down-regulated in the fibrotic border zone of
infracted hearts. Intriguingly, many of the miR-29 downstream target genes, such as FBN1,
COL1A1, COL1A2, ELN and COL3A1, are upregulated after myocardial infarction,
suggesting that they may contribute to miR-29-mediated cardiac fibrosis. Taken together,
these studies indicate that miRNAs are not only important for cardiovascular development,
but also essential factors for cardiac remodeling.
4 miRNAs regulate ischemia and conduction system
Ischemia is an independent risk factor of cardiovascular events, which leads to myocardial
infarction (MI) and ischemia- reperfusion (I/R) injury. Several miRNAs are reported to
participate in the regulation of these pathologic processes, especially the cardiomyocyte
apoptosis following MI and I/R injury. miR-92a, a member of miR-17-92 cluster involved in
cardiomyocyte proliferation, also participated in the control of cardiomyocyte survival
through targeting integrin subunit α5 and eNOS [84]. Inhibition of miR-92a by antagomir
has improved cardiac function and deduced cardiomyocyte apoptosis after myocardial
infraction in mice. miR-21 serves as an anti-apoptotic factor in MI animal models through
targeting PDCD4 and repressing its expression [85]. Unlike miR-21, miR-1/206 acts as a
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tpro-apoptotic factor by repressing the anti-apoptosis gene IGF-1 in infracted heart. Both
IGF-1 loss-of-function and miR-1/206 gain-of-function can increase caspase-3-mediated
apoptotic signaling pathway [86]. Additionally, miR-320 is downregulated after I/R injury.
Gain- and loss-of-function studies demonstrated that miR-320 promotes cardiomyocyte
apoptosis via maintaining the HSP20 levels [87].
The cardiac conduction system can be damaged following cardiac injury, such as cardiac
ischemia or acute MI. Cellular necrosis in the lesion region is able to cause the dysfunction
of the whole cardiac conduction system, including sinoatrial node, atrioventricular node and
His-Purkinje system. Some of the defects include that the electrical signals could not be
conducted smoothly through this conduction system, following a series of arrhythmia.
miRNAs have been shown to participate in this process and the proper expression of
miRNAs is critical for sustaining the normal function of cardiac conduction system. For
instance, it has been reported that miR-1 and miR-133 target several ion channel and gap-
junction associated genes, such as HCN2, HCN4, KCNJ2, ERG and GJA1 (Cx43) [88–90].
Overexpression of miR-1 in infracted myocardium can promote arrhythmogenesis, whereas
arrhythmia could be alleviated through deleting endogenous miR-1 [90]. miR-208a, another
cardiac-specific miRNA, has also been demonstrated to play an important role in
arrhythmogenesis [42], especially in the process of atrial depolarization, by regulating the
expression of Connexin-40 (GJA5). Therefore, studies have established the role of miRNAs
in the development and maintenance of the cardiac conduction system as well as in the
pathology of cardiac ischemia.
5 Conclusion and perspectives
miRNA research has rapidly emerged as an important area within the field of non-coding
RNAs. These newly characterized “small” regulators have proven to play “big” roles in
multiple levels of cellular biological behavior, from cell proliferation, differentiation and
apoptosis, to the maintenance of stem cell self-renewal. From cardiac point of view,
miRNAs have been found to participate in nearly all processes of cardiovascular biology,
such as heart development, cardiomyocyte regeneration, cardiac remodeling, as well as
stress induced injury and heart diseases. However, the identified miRNAs and miRNA-
targets thus far are just the tip of the iceberg, and numerous questions concerning the
relationship between miRNAs and cardiac function remain to be answered.
miRNAs could be utilized as bio-markers for the diagnosis of cardiovascular disease, given
that the expression of many miRNAs is altered in varieties of cardiac biologic processes and
disease conditions. The “circulating mi- RNAs” are stable in mammalian serum and plasma,
which are much easier to acquire, raising the possibility that they could serve as biomarkers
for heart disease diagnosis and prediction [91,92]. Recently, a clinical study has already
made progress toward this possibility by showing the circulating miR-192 level is correlated
with the development of ischemic heart failure after acute myocardial infarction in human
patients [93]. The research for translational medicine of miRNAs has emerged rapidly in
recent years. Though the therapeutic potential of miRNAs in cardiovascular disease remains
debatable, much remarkable progress has been made. Cardiologists are now attempting to
use miRNAs and/or their inhibitors to treat heart diseases. Along with that, many efficient
techniques to manipulate miRNA levels in vivo have been developed. Among them,
antagomirs, which knock down targeted miRNAs via sequestering them from the functional
complex, were shown to be stable in the blood [94]. Conversely, miRNA mimic, a
synthesized chemically modified double-stranded oligonucleotide, can achieve the gain-of-
function of specific miRNA in vitro and in vivo [95,96]. Additionally, rAAV9 vector has
been demonstrated of high affinity for myocardium, which means it can be used for
delivering miRNA-related therapeutic molecules to the heart specifically through
Wu et al. Page 6
Sci China Life Sci. Author manuscript; available in PMC 2014 October 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tintravenous injection [97]. With these efficient strategies for gain- and loss-of-function of
the molecular mechanism and therapeutic application of miRNAs in cardiovascular disease,
much more fruitful work about the molecular mechanism and therapeutic application of
miRNAs in cardiovascular disease will emerge. We are confident that the diagnosis and
therapeutics based on miRNA will play an even more important role in the field of gene
therapy.
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